RT Journal Article
SR Electronic
T1 Identification of potential biomarkers or therapeutic targets of mesenchymal stem cells in multiple myeloma by bioinformatics analysis
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.06.16.153676
DO 10.1101/2020.06.16.153676
A1 Zhi-Ran Li
A1 Wen-Ke Cai
A1 Qin Yang
A1 Ming-Li Shen
A1 Hua-Zhu Zhang
A1 Qian Huang
A1 Gui-Xin Zhao
A1 Ke-Yan Chen
A1 Gong-Hao He
YR 2020
UL http://biorxiv.org/content/early/2020/06/16/2020.06.16.153676.abstract
AB Objectives Mesenchymal stem cells (MSCs) play important roles in multiple myeloma (MM) pathogenesis. Previous studies have discovered a group of MM-associated potential biomarkers in MSCs derived from bone marrow (BM-MSCs). However, no study of the bioinformatics analysis was conducted to explore the key genes and pathways of MSCs derived from adipose (AD-MSCs) in MM. The aim of this study was to screen potential biomarkers or therapeutic targets of AD-MSCs and BM-MSCs in MM.Methods The gene expression profiles of AD-MSCs (GSE133346) and BM-MSCs (GSE36474) were downloaded from Gene Expression Omnibus (GEO) database. Gene Oncology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interaction (PPI) network of differentially expressed genes (DEGs) were performed.Results A total of 456 common downregulated DEGs in two datasets were identified and the remaining DEGs in GSE133346 were further identified as specific DEGs of AD-MSCs. Furthermore, a PPI network of common downregulated DEGs was constructed and seven hub genes were identified. Importantly, cell cycle was the most significantly enrichment pathway both in AD-MSCs and BM-MSCs from MM patients.Conclusion We identified key genes and pathways closely related with MM progression, which may act as potential biomarkers or therapeutic targets of MM.Competing Interest StatementThe authors have declared no competing interest.